Evidence map›Paper›PMID 40418326›Full record

ArticleVirchows Archiv : an international journal of pathology2025

FGFR3 amplification is predictive of poor prognosis in esophageal squamous cell carcinoma patients.

Xiang Wang, Jie Huang, Chen Xu, Lili Zhang, Jieakesu Su, Jia Liu, Licheng Shen, Lijuan Luan, Yingyong Hou

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiang Wang *Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jie Huang *Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chen XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Lili ZhangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jieakesu SuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jia LiuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Licheng ShenDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Lijuan LuanDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China. luan.lijuan@zs-hospital.sh.cn.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China. houyingyong@aliyun.com.ORCID http://orcid.org/0000-0001-9156-2305

Funding

National Key Clinical Specialty Discipline Construction Program of China No.YWP2023-001Shanghai Natural Science Foundation of China No.23ZR1410000Shanghai Natural Science Foundation of China No.23ZR1410200
6 · The paper itself

Abstract

Identification and verification of clinically actionable molecular variations to refine currently adopted risk-stratified treatment strategy for esophageal squamous cell carcinoma (ESCC) is urgently needed. Here, we evaluated FGFR3 amplification status by fluorescence in situ hybridization (FISH) performed on tissue microarrays and its prognostic value in 526 ESCC patients. FGFR3 amplification was found in 3.0% (16/526) of ESCC patients enrolled in this study cohort. Intratumor heterogeneity and metastatic heterogeneity of FGFR3 amplification were found in 10% (2/20) and 40% (2/5) FGFR3 amplified ESCC cases, respectively. No statistically significant associations were found between FGFR3 amplification status and common clinicopathological features. Survival analyses demonstrated that FGFR3 amplification was associated with a worse disease-free survival (DFS) and overall survival (OS) (DFS, P = 0.008; OS, P = 0.027). Univariate and multivariate analyses revealed that invasive depth was significantly associated with DFS (P = 0.001, HR: 1.498, 95% CI: 1.172-1.914) and OS (P = 0.002, HR: 1.482, 95% CI: 1.159-1.894), and FGFR3 amplification was significantly associated with DFS (P = 0.020, HR: 2.065, 95% CI: 1.120-3.808) and tend to associate with OS (P = 0.070, HR: 1.756, 95% CI: 0.954-3.233). Furthermore, when patients were stratified into stage I-II group and stage III-IV group, the adverse effect of FGFR3 amplification on prognosis was presented in stage III-IV patients (DFS, P = 0.0047; OS, P = 0.029) rather than stage I-II patients (DFS, P = 0.46; OS, P = 0.53), indicating that the prognostic value of FGFR3 amplification may relying on clinical stage. Our findings might provide a better understanding of the FGFR3 amplification status in ESCC patients and add further insights into its potential prognostic value.

Indexed as

Biomarkers, TumorEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaGene AmplificationReceptor, Fibroblast Growth Factor, Type 3AdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedPrognosisTissue Array AnalysisBiomarkers, TumorFGFR3 protein, humanReceptor, Fibroblast Growth Factor, Type 3Clinical stageEsophageal cancerEsophageal squamous cell carcinomaFGFR3 amplificationFluorescence in situ hybridizationPrognosis

Identifiers

PMID40418326

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.